论文部分内容阅读
最近资料显示急性髓性白血病 (ＡＭＬ)病人缓解后或缓解诱导阶段用大剂量阿糖胞苷(Ａｒａ ｃ)作早期强化化疗能改善长期无复发生存率 (ＲＦＳ) ,已经有双诱导方案的比较研究报道。本研究评价大剂量和标准剂量Ａｒａ ｃ的效果。病人和方法 1 985年 3月至 1 992年 1 1月72 5例
Recent data have shown that long-term recurrence-free survival (RFS) can be improved by early intensive chemotherapy with high-dose Ara c in patients with acute myeloid leukemia (AML) after remission or in the induction phase of induction, and there has been a comparison of dual induction regimens Research report. This study evaluated the effects of high and standard doses of Ara c. Patients and methods From March 1985 to January 722 725 cases